Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus

Abstract

The occurrence of nephritis is considered to be the most important factor influencing the prognosis in systemic lupus erythematosus (SLE). Despite the apparent histological similarity of the lesions, however, patients with diffuse proliferative glomerulonephritis (DPGN) may exhibit different outcomes. A retrospective study was carried out on 81 SLE patients with DPGN to evaluate the prognostic significance of different clinical, serological and histological variables; in particular, 95 renal biopsies were re-evaluated and the activity and chronicity indices for the patients were determined.

A positive correlation was observed between the presence of chronic lesions on renal biopsy and a poor renal outcome (<0.001). Moreover, in the repeat biopsies the patients with a poor outcome showed a higher degree of chronic lesions. Active lesions and other clinical and serological parameters did not correlate with the outcome.

Keywords

diffuse proliferative glomerulonephritis prognostic factors renal biopsy activity index chronicity index

Get full access to this article

View all access options for this article.

References

Baldwin DS et al. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970; 73: 929-943.

Baldwin DS et al. Lupus nephritis: clinical course as related to morphological forms and their transition. Am J Med 1977; 62: 12.

Austin HA , III et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.

Austin HA , III et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.

Appel GB et al. Long-term follow up of patients with lupus nephritis. A study based on the classification of the WHO. Am J Med 1987; 83: 877-885.

Balow JE Therapeutic trials in lupus nephritis. Problems related to renal histology, monitoring of therapy and measures of outcome. Nephron 1981; 27: 171-176.

Austin HA , Klippel JD , Balow JE Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614-619.

Donadio JV et al. Immunosuppressive drug therapy in lupus nephritis. Am J Kid Dis 1993; 21: 239-250.

Gladman DD Prognosis of systemic lupus erythematosus and the factors that affect it. Curr Opin Rheumatol 1992; 4: 681-687.

10.

Houssiau FA et al. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exper Rheumatol 1991; 9: 345-349.

11.

Seleznick MJ , Fries JF Variables associated with decreased survival in Systemic Lupus Erythematosus. Sem Arthr Rheum 1991; 21: 73—80.

12.

Studensky S. et al. Survival in systemic lupus erythematosus: a multivariate analysis of demographic factors. Arthrits Rheum 1987; 30: 1326-1332.

13.

Swaak Ajg , Nossent JC , Smeenk Rjt. Prognostic factors in systemic lupus erythematosus. Rheumatol Int 1991; 11: 127-132.

14.

Reveille Djd et al. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis and Rheum 1990; 33: 37-48.

15.

Esdaile JM et al. Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. Q J Med 1991; 81: 907-918.

16.

Tan EN et al. The 1982 reviewed for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277.

17.

Henry JB Clinical and Diagnosis Management by Laboratory Methods. Saunders: 1991, pp 121.

18.

Jacobson, Striker , Klahn. The Principles and Practice of Nephrology . Mosby: 1995, pp 10-11. London

19.

Arce-Salinas CA et al. Factors associated with chronic renal failure 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 1995; 4: 197-203.

20.

Vitali C. et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumathology research. I. A descriptive analysis of 704 European lupus patients. Clin Exp Rheumatol 1992; 10: 527-539.

21.

Vitali C. et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumathology research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 541-547.

22.

Vitali C. et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumathology research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 549-554.

23.

Gladman D. et al. Cross cultural validation and reliability of three disease activity indices in systemic lupus erythematosus. J Rheumatol 1992; 19: 608-611.

24.

Petri M. , Hellmann D. , Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 19: 53-59.

25.

Charles PJ , van Venroij WJ , Maini RN and the Consensus Finding Group for Autoantibodies. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases: 1989-1992. Clin Exp Rheumatol 1992; 10: 507-513.

26.

Magil AB et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis . Kidney Int 1987; 34: 511-517.

27.

Balow JE et al. Lupus nephritis. Ann Int Med 1987; 106: 79-94.

28.

Esdaile JM et al. Can experienced clinicians predict the outcome of lupus nephritis ?. Lupus 1992; 1: 205-214.

29.

Nossent HC et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis and Rheum 1990; 33: 970-977.

30.

Schwartz MM et al. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 891-896.

31.

McLaughlin JR et al. Kidney biopsy in systemic lupus erithematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37: 559-567.

32.

Gladman DD et al. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 1989; 73: 1125-1133.

33.

Whiting-O'Keefe Q. et al. The information content from renal biopsy in systemic lupus erithematosus. Ann Int Med 1982; 96: 718-723.

34.

Esdaile JM et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989; 269: 779-833.

35.

McLaughlin JR. I. Kidney biopsy in systemic lupus erithematosus. II. Survival analysis according to biopsy results. Arthritis Rheum 1991; 34: 1268-1273.

36.

Park MH et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44: 309-319.

37.

Williams PS et al. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988; 252: 343-354.

38.

Brazy PC et al. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670-674.

39.

Peterson JC et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Int Med 1995; 123: 754-762.